Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chelsey Vranes

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Gynecologic Oncology Reports|April 29, 2024
Uterine adenosarcoma presenting as uterine inversion: A case studyCaitlin Witt, Chelsey Vranes, Leslie H Clark
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 19, 2026
Immune-Related Adverse Events Among Patients With Endometrial Cancer Receiving Pembrolizumab Alone or With Other Treatments: A Single-Center Real-World ExperienceGlenn Boyles, Chelsey Vranes, Nikita Sinha, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 19, 2022
Mortality Patterns of Synchronous Uterine and Ovarian Cancers: A SEER Registry AnalysisRobert Lee Dood, Lisa M Pappas, Lindsay J Collin, et al.
Cancers|April 14, 2026
Eicosapentaenoic Acid Suppresses Tumor Growth and Enhances Chemosensitivity via AKT/mTOR Signaling in Uterine Serous CarcinomaHaomeng Zhang, Weimin Kong, Xiaochang Shen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 2, 2023
Secondary validation of an ovarian cancer-specific comorbidity index in a US populationChelsey Vranes, Hui Zhao, Mette Calundann Noer, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Gynecologic Oncology Reports|April 29, 2024
Uterine adenosarcoma presenting as uterine inversion: A case studyCaitlin Witt, Chelsey Vranes, Leslie H Clark
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 19, 2026
Immune-Related Adverse Events Among Patients With Endometrial Cancer Receiving Pembrolizumab Alone or With Other Treatments: A Single-Center Real-World ExperienceGlenn Boyles, Chelsey Vranes, Nikita Sinha, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 19, 2022
Mortality Patterns of Synchronous Uterine and Ovarian Cancers: A SEER Registry AnalysisRobert Lee Dood, Lisa M Pappas, Lindsay J Collin, et al.
Cancers|April 14, 2026
Eicosapentaenoic Acid Suppresses Tumor Growth and Enhances Chemosensitivity via AKT/mTOR Signaling in Uterine Serous CarcinomaHaomeng Zhang, Weimin Kong, Xiaochang Shen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 2, 2023
Secondary validation of an ovarian cancer-specific comorbidity index in a US populationChelsey Vranes, Hui Zhao, Mette Calundann Noer, et al.
Pageof 1